- Home
- JLL vs RVTY Comparison
JLL vs RVTY Comparison
Compare JLL & RVTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JLL | RVTY |
|---|---|---|
| Founded | 1997 | 1937 |
| Country | United States | United States |
| Employees | 48000 | N/A |
| Industry | Real Estate | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5B | 11.6B |
| IPO Year | 1997 | 1994 |
Fundamental Metrics
Financial Performance| Metric | JLL | RVTY |
|---|---|---|
| Price | $312.07 | $112.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 16 |
| Target Price | ★ $365.33 | $109.67 |
| AVG Volume (30 Days) | 348.4K | ★ 1.4M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 0.34% |
| EPS Growth | ★ 45.13 | N/A |
| EPS | ★ 3.33 | 0.36 |
| Revenue | ★ $26,115,600,000.00 | $3,311,822,000.00 |
| Revenue This Year | $7.71 | $6.37 |
| Revenue Next Year | $6.99 | $5.10 |
| P/E Ratio | ★ $90.95 | $315.33 |
| Revenue Growth | ★ 11.45 | N/A |
| 52 Week Low | $246.08 | $81.22 |
| 52 Week High | $363.06 | $118.30 |
Technical Indicators
Market Signals| Indicator | JLL | RVTY |
|---|---|---|
| Relative Strength Index (RSI) | 61.03 | 67.64 |
| Support Level | $278.33 | $90.57 |
| Resistance Level | $322.89 | $118.30 |
| Average True Range (ATR) | 9.42 | 4.04 |
| MACD | 2.00 | 0.99 |
| Stochastic Oscillator | 96.50 | 79.75 |
Price Performance
Historical ComparisonAbout JLL Jones Lang LaSalle Incorporated
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $86 billion for clients across diverse public and private real estate strategies as of the end of 2025.
About RVTY Revvity Inc.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.